Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Salix scoops up Santarus for $2.1bn in cash

Executive Summary

Gastrointestinal-focused Salix Pharmaceuticals Ltd. is paying $2.1bn ($32.00 per share in cash; a 35% premium) to acquire all the outstanding stock of fellow public specialty pharmaco Santarus Inc. (acquires, develops, and sells physician specialty products).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Includes Contract
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register